Literature DB >> 22020414

Lipid content and cryotolerance of porcine embryos cultured with phenazine ethosulfate.

B Gajda1, M Romek, I Grad, E Krzysztofowicz, M Bryla, Z Smorag.   

Abstract

The addition of phenazine ethosulfate (PES) to culture medium was investigated for its effect on pig embryo development, apoptosis, cytoplasmic lipid content and survival after OPS vitrification. Porcine zygotes were cultured in NCSU-23 medium supplemented with 0 (control) or 0.05 microM PES up to the blastocyst stage and were vitrified using OPS technology. Culture of embryos with PES reduced the cytoplasmic lipid content, as measured by fluorescence of blastocysts stained with Nile Red. The survival rate of vitrified blastocysts was slightly enhanced, although not significantly, in the presence of PES compared to the PES-free group (45.2 and 37.9 percent, respectively). These results showed that culturing porcine embryos in medium with PES increased the proportion of morula and blastocyst formation and reduced the index of DNA fragmentation and the cytoplasmic lipid content of cultured blastocysts. However, the use of PES during in vitro culture had limited effect on porcine blastocyst survival after vitrification.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22020414

Source DB:  PubMed          Journal:  Cryo Letters        ISSN: 0143-2044            Impact factor:   1.066


  2 in total

1.  Docosahexaenoic acid and phenazine ethosulfate are not efficient lipid modulators for porcine in vitro maturation systems.

Authors:  José Victor Cardoso Braga; Andrez Pastorello Bohn; Luana Pescke Soares; Eliza Rossi Komninou; Thomaz Lucia Júnior; Arnaldo Diniz Vieira; Rafael Gianella Mondadori
Journal:  Vet Res Commun       Date:  2022-01-21       Impact factor: 2.816

Review 2.  A role of lipid metabolism during cumulus-oocyte complex maturation: impact of lipid modulators to improve embryo production.

Authors:  E G Prates; J T Nunes; R M Pereira
Journal:  Mediators Inflamm       Date:  2014-03-06       Impact factor: 4.711

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.